Thienopyrimidine and thienopyridine compounds and methods of use thereof

Inventors: Jolanta Grembecka (Ann Arbor, MI); Tomasz Cierpicki (Ann Arbor, MI); Dmitry Borkin (Ann Arbor, MI); Jonathan Pollock (Ann Arbor, MI); Hongzhi Miao (Ann Arbor, MI); Duxin Sun (Ann Arbor, MI); Liansheng Li (La Jolla, CA); Tao Wu (La Jolla, CA); Jun Feng (La Jolla, CA); Pingda Ren (La Jolla, CA); Yi Liu (La Jolla, CA)

Assignees: THE REGENTS OF THE UNIVERSITY OF MICHIGAN; KURA ONCOLOGY, INC.

C07D495/04 C07D519/00 C07F9/5325 C07F9/65583

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 10,246,464
App. No.: 15/509,989
Granted: Apr 2, 2019
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The present disclosure provides compounds and methods for inhibiting the interaction of menin with its upstream or downstream signaling molecules including but not limited to MLL1, MLL2 and MLL-fusion oncoproteins. Compounds of the disclosure may be used in methods for the treatment of a wide variety of cancers and other diseases associated with one or more of MLL1, MLL2, MLL fusion proteins, and menin.

Claims (36)

1. A compound represented by the structure of Formula (4):

or a salt thereof, wherein:

R 1 , R 2 , R 4 , R 5 , R 8 , and R a are independently selected from hydrogen, halogen, —OR 20 , —SR 20 , —N(R 20 ) 2 , —N(R 20 )C(O)R 20 , —C(O)R 20 , —C(O)OR 20 , —C(O)N(R 20 ) 2 , —OC(O)R 20 , —S(O) 2 R 20 , —S(O) 2 N(R 20 ) 2 , —N(R 20 )S(O) 2 R 20 , —NO 2 , —P(O)(OR 20 ) 2 , —P(O)(R 20 ) 2 , —OP(O)(OR 20 ) 2 , —CN, C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, —OR 20 , —SR 20 , —N(R 20 ) 2 , —N(R 20 )C(O)R 20 , —C(O)R 20 , —C(O)OR 20 , —C(O)N(R 20 ) 2 , —OC(O)R 20 , —S(O) 2 R 20 , —S(O) 2 N(R 20 ) 2 , —N(R 20 )S(O) 2 R 20 , —NO 2 , ═O, ═S, ═N(R 20 ), —P(O)(OR 20 ) 2 , —P(O)(R 20 ) 2 , —OP(O)(OR 20 ) 2 , —CN, C 3-10 carbocycle, and 3- to 10-membered heterocycle, or two substituents on the same carbon atom of an C 1-6 alkyl, C 2-6 alkenyl, or C 2-6 alkynyl come together to form a C 3-10 carbocycle or 3- to 10-membered heterocycle; and C 3-10 carbocycle and 3- to 10-membered heterocycle; wherein any C 3 -10 carbocycle and 3- to 10-membered heterocycle of R 1 , R 2 , R 4 , R 5 , R 8 , and R a is independently optionally substituted with one or more substituents selected from halogen, —OR 20 , —SR 20 , —N(R 20 ) 2 , —N(R 20 )C(O)R 20 , —C(O)R 20 , —C(O)OR 20 , —C(O)N(R 20 ) 2 , —OC(O)R 20 , —S(O) 2 R 20 , —S(O) 2 N(R 20 ) 2 , —N(R 20 )S(O) 2 R 20 , —NO 2 , ═O, ═S, ═N(R 20 ), —P(O)(OR 20 ) 2 , —P(O)(R 20 ) 2 , —OP(O)(OR 20 ) 2 , —CN, C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl;

R 3 is selected from selected from hydrogen, —C(O)R 20 , —C(O)OR 20 , —C(O)N(R 20 ) 2 , —S(O) 2 R 20 , —S(O) 2 N(R 20 ) 2 , C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, —OR 20 , —SR 20 , —N(R 20 ) 2 , —N(R 20 )C(O)R 20 , —C(O)R 20 , —C(O)OR 20 , —C(O)N(R 20 ) 2 , —OC(O)R 20 , —S(O) 2 R 20 , —S(O) 2 N(R 20 ) 2 , —N(R 20 )S(O) 2 R 20 , —NO2, ═O, ═S, ═N(R 20 ), —P(O)(OR 20 ) 2 , —P(O)(R 20 ) 2 , —OP(O)(OR 20 ) 2 , —CN, C 3-10 carbocycle, and 3- to 10-membered heterocycle, or two substituents on the same carbon atom of an C 1-6 alkyl, C 2-6 alkenyl, or C 2-6 alkynyl come together to form a C 3-10 carbocycle or 3- to 10-membered heterocycle; and C 3-10 carbocycle and 3- to 10-membered heterocycle; wherein any C 3-10 carbocycle and 3- to 10-membered heterocycle of R 3 is independently optionally substituted with one or more substituents selected from halogen, —OR 20 , —SR 20 , —N(R 20 ) 2 , —N(R 20 )C(O)R 20 , —C(O)R 20 , —C(O)OR 20 , —C(O)N(R 20 ) 2 , —OC(O)R 20 , —S(O) 2 R 20 , —S(O) 2 N(R 20 ) 2 , —N(R 20 )S(O) 2 R 20 , —NO 2 , ═O, ═S, ═N(R 20 ), —P(O)(OR 20 ) 2 , —P(O)(R 20 ) 2 , —OP(O)(OR 20 ) 2 , —CN, C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl;

R 6 is independently selected at each occurrence from halogen, —OR 20 , —SR 20 , —N(R 20 ) 2 , —N(R 20 )C(O)R 20 , —C(O)R 20 , —C(O)OR 20 , —C(O)N(R 20 ) 2 , —OC(O)R 20 , —S(O) 2 R 20 , —S(O) 2 N(R 20 ) 2 , —N(R 20 )S(O) 2 R 20 , —NO 2 , —P(O)(OR 20 ) 2 , —P(O)(R 20 ) 2 , —OP(O)(OR 20 ) 2 , —CN, C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, —OR 20 , —SR 20 , —N(R 20 ) 2 , —N(R 20 )C(O)R 20 , —C(O)R 20 , —C(O)OR 20 , —C(O)N(R 20 ) 2 , —OC(O)R 20 , —S(O) 2 R 20 , —S(O) 2 N(R 20 ) 2 , —N(R 20 )S(O) 2 R 20 , —NO 2 , ═O, ═S, ═N(R 20 ), —P(O)(OR 20 ) 2 , —P(O)(R 20 ) 2 , —OP(O)(OR 20 ) 2 , —CN, C 3-10 carbocycle, and 3- to 10-membered heterocycle, or two substituents on the same carbon atom of an C 1-6 alkyl, C 2-6 alkenyl, or C 2-6 alkynyl come together to form a C 3-10 carbocycle or 3- to 10-membered heterocycle; and C 3 -10o carbocycle and 3- to 10-membered heterocycle; wherein any C 3-10 carbocycle and 3- to 10-membered heterocycle of R 6 is independently optionally substituted with one or more substituents selected from halogen, —OR 20 , —SR 20 , —N(R 20 ) 2 , —N(R 20 )C(O)R 20 , —C(O)R 20 , —C(O)OR 20 , C(O)N(R 20 ) 2 , —OC(O)R 20 , —S(O) 2 R 20 , —S(O) 2 N(R 20 ) 22 , —N(R 20 )S(O) 2 R 20 , —NO 2 , ═O, ═S, ═N(R 20 ), —P(O)(OR 20 ) 2 , —P(O)(R 20 ) 2 , —OP(O)(OR 20 ) 2 , —CN, C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl;

R 20 at each occurrence is independently selected from hydrogen; C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, —OR 30 , —SR 30 , —N(R 30 ) 2 , —N(R 30 )C(O)R 30 , —C(O)R 30 , —C(O)OR 30 , —C(O)N(R 30 ) 2 , —OC(O)R 30 , —S(O) 2 R 30 , —S(O) 2 N(R 30 ) 2 , —N(R 30 )S(O) 2 R 30 , —NO 2 , —P(O)(OR 30 ) 2 , —P(O)(R 30 ) 2 , —OP(O)(OR 30 ) 2 , and —CN; and 3- to 10-membered heterocycle and C 3-10 carbocycle;

R 30 at each occurrence is independently selected from hydrogen, C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl;

Y is N or C(R a );

L is absent or selected from alkylene and heteroalkylene;

s is selected from 0, 1, 2, 3, and 4;

R 7a is -G-V-R 9a :

G is selected from alkylene, heteroalkylene, C 3-12 carbocycle, 3- to 12-membered heterocycle, and combinations thereof, wherein G is optionally substituted with one or more R 32 groups;

V is selected from a C 3-12 carbocycle, and 3- to 12-membered heterocycle;

wherein V is optionally substituted with one or more R 32 groups;

R 9a is selected from halogen, —SR 20 , —N(R 20 ) 2 , —N(R 20 )C(O)R 20 , —C(O)OR 20 , —OC(O)R 20 , —N(R 20 )S(O) 2 R 20 , —NO 2 , =S, =N(R 20 ), —P(O)(OR 20 ) 2 , —P(O)(R 20 ) 2 , —OP(O)(OR 20 ) 2 , —CN, C 2-6 alkenyl, and C 2-6 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, —OR 20 , —SR 20 , —N(R 20 ) 2 , —N(R 20 )C(O)R 20 , —C(O)R 20 , —C(O)OR 20 , —C(O)N(R 20 ) 2 , —OC(O)R 20 , —S(O) 2 R 20 , —S(O) 2 N(R 20 ) 2 , —N(R 20 )S(O) 2 R 20 , —NO 2 , ═O, ═S, ═N(R 20 ), —P(O)(OR 20 ) 2 , —P(O)(R 20 ) 2 , —OP(O)(OR 20 ) 2 , —CN, C 3-10 carbocycle, and 3- to 10-membered heterocycle; C 3-10 carbocycle and 3- to 10-membered heterocycle; or two R 32 on the same carbon atom can come together to form a C 3-10 carbocycle or 3- to 10-membered heterocycle, wherein each C 3-10 carbocycle and 3- to 10-membered heterocycle of R 32 is independently optionally substituted with one or more substituents selected from halogen, —OR 20 , —SR 20 , —N(R 20 ) 2 , —N(R 20 )C(O)R 20 , —C(O)R 20 , —C(O)OR 20 , —C(O)N(R 20 ) 2 , —OC(O)R 20 , —S(O) 2 R 20 , —S(O) 2 N(R 20 ) 2 , —N(R 20 )S(O) 2 R 20 , —NO 2 , ═O, ═S, ═N(R 20 ), —P(O)(OR 20 ) 2 , —P(O)(R 20 ) 2 , —OP(O)(OR 20 ) 2 , —CN, C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl; and

R 32 at each occurrence is selected from halogen, —OR 20 , —SR 20 , —N(R 20 ) 2 , —N(R 20 )C(O)R 20 , —C(O)R 20 , —C(O)OR 20 , —C(O)N(R 20 ) 2 , —OC(O)R 20 , —S(O) 2 R 20 , —S(O) 2 N(R 20 ) 2 , —N(R 20 )S(O) 2 R 20 , —NO 2 , ═O, ═S, ═N(R 20 ), —P(O)(OR 20 ) 2 , —P(O)(R 20 ) 2 , —OP(O)(OR 20 ) 2 , —CN, C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, —OR 20 , —SR 20 , —N(R 20 ) 2 , —N(R 20 )C(O)R 20 , —C(O)R 20 , —C(O)OR 20 , —C(O)N(R 20 ) 2 , —OC(O)R 20 , —S(O) 2 R 20 , —S(O) 2 N(R 20 ) 2 , —N(R 20 )S(O) 2 R 20 , —NO 2 , ═O, ═S, ═N(R 20 ), —P(O)(OR 20 ) 2 , —P(O)(R 20 ) 2 , —OP(O)(OR 20 ) 2 , —CN, C 3-10 carbocycle, and 3- to 10-membered heterocycle; C 3-10 carbocycle and 3- to 10-membered heterocycle; or two R 32 on the same carbon atom can come together to form a C 3-10 carbocycle or 3- to 10-membered heterocycle, wherein each C 3-10 carbocycle and 3- to 10-membered heterocycle of R 32 is independently optionally substituted with one or more substituents selected from halogen, —OR 20 , —SR 20 , —N(R 20 ) 2 , —N(R 20 )C(O)R 20 , —C(O)R 20 , —C(O)OR 20 , —C(O)N(R 20 ) 2 , —OC(O)R 20 , —S(O) 2 R 20 , —S(O) 2 N(R 20 ) 2 , —N(R 20 )S(O) 2 R 20 , —NO 2 , ═O, ═S, ═N(R 20 ), —P(O)(OR 20 ) 2 , —P(O)(R 20 ) 2 , —OP(O)(OR 20 ) 2 , —CN, C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl.

2. The compound or salt of claim 1 , wherein R 1 and R 2 are independently selected from hydrogen, halogen, —OH, —CN, —NO 2 , —NH 2 , C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 haloalkenyl, C 2-6 alkynyl, and C 2-6 haloalkynyl.

3. The compound or salt of claim 2 , wherein R 1 is selected from halogen, C 1-6 haloalkyl, C 2-6 haloalkenyl, and C 2-6 haloalkynyl.

4. The compound or salt of claim 3 , wherein R 1 is selected from —CH 2 CF 3 and —CH 2 CHF 2 .

5. The compound or salt of claim 2 , wherein R 2 is selected from hydrogen, halogen, —OH, —CN, —NO 2 , —NH 2 , C 1-6 alkyl, and C 1-6 alkoxy.

6. The compound or salt of claim 5 , wherein R 2 is hydrogen.

7. The compound or salt of claim 1 , wherein R 3 , R 4 , and R 5 are each hydrogen.

8. The compound or salt of claim 1 , wherein R 6 , at each occurrence, is independently selected from halogen, —OH, C 1-6 alkyl, and C 1-6 alkoxy.

9. The compound or salt of claim 1 , wherein R 8 is selected from hydrogen, halogen, —OH, —CN, —NO 2 , —NH 2 , C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 haloalkenyl, C 2-6 alkynyl, and C 2-6 haloalkynyl.

10. The compound or salt of claim 9 , wherein R 8 is —CN.

11. The compound or salt of claim 1 , wherein Y is N.

12. The compound or salt of claim 1 , wherein L is absent.

13. The compound or salt of claim 1 , wherein G is alkylene optionally substituted with one or more R 32 groups.

14. The compound or salt of claim 13 , wherein G is selected from:

15. The compound or salt of claim 1 , wherein V is selected from azetidine, oxetane, piperidine, oxane, piperazine, pyrrolidine, tetrahydrofuran, thiolane, imidazolidine, morpholine, thiomorpholine, azepane, and homopiperazine, any one of which is optionally substituted with one or more R 32 groups.

16. The compound or salt of claim 1 , wherein V is selected from phenyl, pyridine, pyrazine, pyrimidine, pyridazine, naphthalene, anthracene, quinoline, isoquinoline, quinoxaline, acridine, quinazoline, cinnoline, phthalazine, furan, dihydrofuran, thiophene, dihydrothiophene, imidazole, imidazoline, oxazole, oxazoline, pyrrole, dihydropyrrole, thiazole, dihydrothiazole, pyrazole, dihydropyrazole, isoxazole, dihydroisoxazole, isothiazole, dihydroisothiazole, benzofuran, isobenzofuran, indole, isoindole, benzothiophene, benzimidazole, purine, indazole, benzoxazole, benzisoxazole, and benzothiazole, any one of which is optionally substituted with one or more R 32 groups.

17. The compound or salt of claim 1 , wherein R 9a is

18. A compound selected from:

or a salt thereof.

19. A pharmaceutical composition, comprising a compound of claim 1 , or a salt thereof, and a pharmaceutically acceptable carrier or excipient.

20. A method for the treatment of a disease, comprising administering a compound of claim 1 , or a salt thereof, to a subject suffering from said disease, wherein said disease is leukemia, hematologic malignancies, solid tumor cancer, glioma, or diabetes.

Assignments (9)